Idarubisin

Idarubisin
Nama sistematis (IUPAC)
	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxo-α-L-lyxo-hexopyranoside
Data klinis
AHFS/Drugs.com	monograph
MedlinePlus	a691004
Kat. kehamilan	D(US)
Status hukum	℞-only (US)
Data farmakokinetik
Ikatan protein	97%
Waktu paruh	22 hours
Pengenal
Nomor CAS	58957-92-9
Kode ATC	L01DB06
PubChem	CID 42890
Ligan IUPHAR	7083
DrugBank	DB01177
ChemSpider	39117
UNII	ZRP63D75JW
KEGG	D08062
ChEBI	CHEBI:42068
ChEMBL	CHEMBL1117
Sinonim	9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione
Data kimia
Rumus	C26H27NO9
SMILES	eMolecules & PubChem
	InChI InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1 ; Key:XDXDZDZNSLXDNA-TZNDIEGXSA-N ;

Idarubisin (/ˌaɪdəˈruːbɪsɪn/) atau 4-demetoksidaunorubisin adalah obat antileukemia antrasiklin. Obat ini menyisipkan^[1] dirinya ke dalam DNA dan mencegah DNA terurai dengan mengganggu enzim topoisomerase II. Obat ini merupakan analog daunorubisin, tetapi tidak adanya gugus metoksi meningkatkan kelarutan lemak dan penyerapan selulernya.^[2] Mirip dengan antrasiklin lainnya, obat ini juga menginduksi pengusiran histon dari kromatin.^[3]

Obat ini termasuk dalam golongan obat yang disebut "antibiotik antitumor".

Obat ini saat ini dikombinasikan dengan sitosin arabinosida sebagai pengobatan lini pertama leukemia mieloid akut.^[4]

Obat ini digunakan untuk pengobatan leukemia limfoblastik akut dan leukemia mielogenus kronis dalam krisis blast.^[5]

Efek samping

Diare, kram perut, mual dan muntah sering terjadi pada pasien yang diobati dengan idarubisin.^[6]

Referensi

^ Miller JP, Stoodley RJ (2013). "Studies directed towards anthracyclinone syntheses: The use of d-glucose as a chiral auxiliary in asymmetric Diels–Alder reactions". J. Saudi Chem. Soc. 17: 29–42. doi:10.1016/j.jscs.2011.02.019 .
^ "Idamycin Package insert" (PDF). Pfizer. January 2006.
^ Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, et al. (2013). "Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin". Nature Communications. 4: 1908. Bibcode:2013NatCo...4.1908P. doi:10.1038/ncomms2921. PMC 3674280 . PMID 23715267.
^ Arwanih EY, Louisa M, Rinaldi I, Wanandi SI (December 2022). "Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review". Cureus. 14 (12): e33165. doi:10.7759/cureus.33165 . PMC 9885730  Periksa nilai |pmc= (bantuan). PMID 36726936 Periksa nilai |pmid= (bantuan).
^ Katzung BG (2017-11-30). Basic & clinical pharmacology. McGraw-Hill Education. ISBN 9781259641152. OCLC 1009849139.
^ "Idarubicin Side Effects: Common, Severe, Long Term". Drugs.com (dalam bahasa Inggris). Diakses tanggal 2019-06-21.

Pranala luar

Idarubicin bound to proteins in the PDB

[Miller-1] Miller JP, Stoodley RJ (2013). "Studies directed towards anthracyclinone syntheses: The use of d-glucose as a chiral auxiliary in asymmetric Diels–Alder reactions". J. Saudi Chem. Soc. 17: 29–42. doi:10.1016/j.jscs.2011.02.019 .

[2] "Idamycin Package insert" (PDF). Pfizer. January 2006.

[Pang-3] Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, et al. (2013). "Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin". Nature Communications. 4: 1908. Bibcode:2013NatCo...4.1908P. doi:10.1038/ncomms2921. PMC 3674280 . PMID 23715267.

[4] Arwanih EY, Louisa M, Rinaldi I, Wanandi SI (December 2022). "Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review". Cureus. 14 (12): e33165. doi:10.7759/cureus.33165 . PMC 9885730  Periksa nilai |pmc= (bantuan). PMID 36726936 Periksa nilai |pmid= (bantuan).

[5] Katzung BG (2017-11-30). Basic & clinical pharmacology. McGraw-Hill Education. ISBN 9781259641152. OCLC 1009849139.

[6] "Idarubicin Side Effects: Common, Severe, Long Term". Drugs.com (dalam bahasa Inggris). Diakses tanggal 2019-06-21.

[1]

[2]

[3]

[4]

[5]

[6]